Cardiovascular manifestations of substance abuse: Part 2: Alcohol, amphetamines, heroin, cannabis, and caffeine

Heart Disease

Volumn 5, Issue 4, 2003, Pages 253-271

  Frishman, William H ^a,d   Del Vecchio, Alexander ^b   Sanal, Shirin ^a   Ismail, Anjum ^c  

^a WESTCHESTER MEDICAL CENTER   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c Heart Institute of Nevada   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Alcohol; Amphetamines; Caffeine; Cardiovascular disease; Heroin; Marijuana; Substance abuse

Indexed keywords

ALCOHOL; AMPHETAMINE DERIVATIVE; APOLIPOPROTEIN A1; CAFFEINE; CANNABIS; CHOLESTEROL ESTER TRANSFER PROTEIN; DIAMORPHINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; OPIATE; PROSTACYCLIN;

ACUTE DISEASE; ALCOHOL CONSUMPTION; ALCOHOLIC CARDIOMYOPATHY; ALCOHOLISM; CANNABIS ADDICTION; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; COGNITIVE DEFECT; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HEART ARRHYTHMIA; HEART INFARCTION; HEART PROTECTION; HEMOSTASIS; HEROIN DEPENDENCE; HUMAN; HYPERCOAGULABILITY; HYPERTENSION; ISCHEMIC HEART DISEASE; ORTHOSTATIC HYPOTENSION; PERIPHERAL VASCULAR DISEASE; REVIEW; RISK ASSESSMENT; STROKE; SUBSTANCE ABUSE; THROMBOCYTE FUNCTION;

ALCOHOL-RELATED DISORDERS; AMPHETAMINE-RELATED DISORDERS; CAFFEINE; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM STIMULANTS; HEROIN DEPENDENCE; HUMANS; MARIJUANA ABUSE;

EID: 0042121553     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hdx.0000080713.09303.a6     Document Type: Review

References (247)

1. Frishman WH. Alcohol as a cardioprotective agent (editorial). Heart Dis. 2002;4:273-274.
2. Rimm EB, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine or spirits? BMJ. 1996;312:731-736.
3. Zuger A. The case for drinking (all together now: in moderation!). New York Times. December 31, 2002. Science section.
4. Rubin E, Urbano-Marquez A. Alcoholic cardiomyopathy. Alcohol Clin Exp Res. 1994;18:111-114.
5. Preedy VR, Richardson PJ. Ethanol induced cardiovascular disease. Br Med Bull. 1994;1:152-163.
6. McKenna CJ, Codd MB, McCann HA, Sugrue DD. Alcohol consumption and idiopathic dilated cardiomyopathy:a case control study. Am Heart J. 1998;135:833-837.
7. Piano MR, Schwertz DW. Alcoholic heart disease. Heart Lung. 1994; 23:3-17.
8. Regan TJ, Ettinger PO, Halder B, et al. The role of ethanol in cardiac disease. Ann Rev Med. 1977;28:393-409.
9. Mouschmousch B, Abi-Monsour P. Alcohol and the heart:the long term effect of alcohol on the cardiovascular system. Arch Intern Med. 1991;151:36-41.
10. Urbano-Marquez A, Estruch R, Navarro-Lopez F, et al. The effects of alcoholism on skeletal and cardiac muscle. N Engl J Med. 1989;320: 409-415.
11. Timmis GC, Ramos RC, Gordon S, Gangadharan V. The basis for differences in ethanol induced myocardial depression in normal subjects. Circulation. 1975;51:1144-1148.
12. Fernandez-Sola J, Nicolas JM, Oriola J, et al. Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy. Ann Intern Med. 2002;137:321-326.
13. Lazarevic AM, Nakatani S, Neskovic AN, et al. Early changes in left ventricular function in chronic asymptomatic alcoholics:relation to duration of heavy drinking. J Am Coll Cardiol. 2000;35:1599-1606.
14. Capasso JM, Li P, Guideri G, Anversa P. Left ventricular dysfunction induced by chronic alcohol ingestion in rats. Am J Physiol. 1991;261: H212-H219.
15. Moriya N, Nihira M, Sato S, Wantabe T. Ultrastructural changes of liver, heart, lung and kidney. Jpn J Alcohol Stud Drug Depend. 1992;27:189-200.
16. Segel LD, Rendig SV, Choquet Y, et al. Effects of chronic graded ethanol consumption on the metabolism, ultrastructure and mechanical function of the rat heart. Cardiovasc Res. 1975;9:649-663.
17. Siddiq T, Salisbury JR, Richardson PJ, Preedy VR. Synthesis of ventricular mitochondrial proteins in vivo:effect of acute ethanol toxicity. Alcoholism: Clin Exp Res. 1993;17:894-899.
18. Preedy VR, Patel VB, Why HJ, et al. Alcohol and the heart: biochemical alterations. Cardiovasc Res. 1996;139-147.
19. Urbano-Marquez A, Estruch R, Fernandez-Sola J, et al. The greater risk of alcoholic cardiomyopathy and myopathy in women. JAMA. 1995; 274:149-154.
20. Kupari M., Koskinen P. Comparison of the cardiotoxicity of ethanol in women versus men. Am J Cardiol. 1992;70:645-649.
21. Altura BM, Altura BT, Gebrewold A. Comparative effects of ethanol, acetaldehyde and acetate on arterioles and venules in skeletal muscle: direct in situ studies on the microcirculation and their possible relationship to alcoholic myopathy. Microcirc Endothelium Lymphatics. 1990;6:107-126.
22. Guarnieri T, Lakatta EG. Mechanism of myocardial contractile depression by clinical concentration of ethanol. A study of ferret papillary muscles. J Clin Invest. 1990;85:1462-1467.
23. Adams MA, Hirst M. Lack of cardiac alpha 1 adrenoceptor involvement in ethanol induced cardiac hypertrophy. Can J Physiol Pharmacol. 1989;67:240-245.
24. Adams MA, Hirst M. Metoprolol suppresses the development of ethanol induced cardiac hypertrophy in the rat. Can J Physiol Pharmacol. 1990;68:562-567.
25. Demakis JG, Proskey A, Rahimtoola SH, et al. The natural course of cardiomyopathy. Ann Intern Med. 1974;80:293-297.
26. Guillo P, Mansourati J, Maheu B, et al. Long-term prognosis in patients with alcoholic cardiomyopathy and severe heart failure after total abstinence. Am J Cardiol. 1997;79:1276-1278.
27. Gavazzi A, De Maria R, Parolini M, et al. On behalf of the Italian Multicenter Cardiomyopathy Study Group (SPIC). Am J Cardiol. 2000;85:1114-1118.
28. Nicolas JM, Fernandez-Sola J, Estruch R, et al. The effect of controlled drinking in alcoholic cardiomyopathy. Ann Intern Med. 2002;136:192-200.
29. Fauchier L, Babuty D, Poret P, et al. Comparison of long term outcome of alcoholic and idiopathic dilated cardiomyopathy. Eur Heart J. 2000;21:267-269.
30. Prazak P, Pfisterer M, Osswald S, et al. Differences of disease progression in congestive heart failure due to alcoholic as compared to idiopathic dilated cardiomyopathy. Eur Heart J. 1996;17:251-257.
31. Beilin LJ, Puddey IB. Alcohol, hypertension and cardiovascular disease-implications for management. Clin Exp Hypertens. 1993;15:1157-1170.
32. Klatsky AL, Friedman GD, Sigelaub AB, Gerard MJ. Alcohol consumption and blood pressure K. P. M. H. E. data. N Engl J Med. 1977;296:1194-2000.
33. Liu K, Ruth KJ, Flack JM. Blood pressure in young blacks and whites:relevance of obesity and lifestyle factors in determining the differences The CARDIA study. Circulation. 1996;93:60-66.
34. Tsuruta M, Adachi H, Hirai Y, et al. Association between alcohol intake and development of hypertension in Japanese normotensive men:12 year follow-up study. Am J Hypertens. 2000;13:482-487.
35. Fuchs FD, Chambless LE, Kieran P, et al. Alcohol consumption and the incidence of hypertension. The Atherosclerosis Risk in Communities Study. Hypertens. 2001;37:1242-1250.
36. Vriz O, Piccolo D, Cozzutti E, et al, on behalf of the HARVEST Study Group. The effects of alcohol consumption on ambulatory blood pressure and target organs in subjects with border-line to mild hypertension. Cardiovasc Rev Rep. 1998;19:48-52.
37. Aguilera MT, de la Sierra A, Coca A, et al. Effect of alcohol abstinence on blood pressure. Assessment by 24 hour ambulatory blood pressure monitoring. Hypertension. 1999;33:653-657.
38. King AC, Errico AL, Parsons OA, Locallo WR. Blood pressure dysregulation associated with alcohol withdrawal. Alcoholism. Clin Exp Res. 1991;15:478-482.
39. Randin D, Vollenweider P, Tappy L, et al. Suppression of alcohol-induced hypertension by dexamethasone. N Engl J Med. 1995;332:1733.
40. Adeniyi FA. Interactive role of monovalent and divalent cations in pathogenesis of hypertension caused by alcohol. J Clin Pathol. 1986; 39:1264-1268.
41. Arkwright PD, Beilin LJ, Vandongen R, et al. Plasma calcium and cortisol as predisposing factors to alcohol related blood pressure elevation. J Hypertens. 1984;2:387-392.
42. Suter PM, Maire R, Vetter W. Is an increased waist:hip ratio the cause of alcohol-induced hypertension? The AIR94 Study. J Hypertens. 1995; 13:1857-1862.
43. Hsieh ST, Saito K, Miyajima T, et al. Effects of alcohol moderation on blood pressure and intracellular cation in mild essential hypertension. Am J Hypertens. 1995;8:696-703.
44. Hsieh ST, Sano H, Saito K, et al. Magnesium supplementation prevents the development of alcohol induced hypertension. Hypertension. 1992; 19:175-182.
45. Altura BM, Altura BT. Magnesium ions and contraction of vascular smooth muscle. Fed Proc. 1981;40:2672-2679.
46. Hasselbach W, Fassold E, Migala A, Rauch B. Magnesium dependence of sarcoplasmic reticulum calcium transport. Fed Proc. 1981;2657-2661.
47. Altura BM, Altura BT, Carella A. Magnesium deficiency induced spasms of umbilical vessels relation to preeclampsia, hypertension, growth retardation. Science. 1983;221:376-378.
48. Motoyama T, Sano H, Fukuzaki H. Oral magnesium supplementation in patients with essential hypertension. Hypertension. 1989;13:227-232.
49. Carryl OR, Gallardo-Carpentier A, Carpentier RG. Effects of nicotine and ethanol on rat atrial membrane potentials. Alcohol. 1992;9:87-92.
50. Maheswaran R, Beevers M, Beevers DG. Effectiveness of advice to reduce alcohol consumption in hypertensive patients. Hypertension. 1992;19:79-84.
51. Parker M, Puddey IB, Beilin LJ, Vandongen R. Two-way factorial study of alcohol and salt restriction in treated hypertensive men. Hypertension. 1990;16:398-406.
52. Puddey IB, Beilin LJ, Vandongen R. Regular alcohol use raises blood pressure in treated hypertensive subjects. Lancet. 1987;1:647-651.
53. Cushman WC, Cutler JA, Hanna E, et al, for the PATHS Group. Prevention and treatment of hypertension study (PATHS): effects of an alcohol treatment program on blood pressure. Arch Intern Med. 1998; 158:1197-1207.
54. Narkiewicz K, Cooley RL, Somers VK. Alcohol potentiates orthostatic hypotension. Implications for alcohol-related syncope. Circulation. 2000;101:398-402.
55. Rossinen J, Sinisalo J, Partanen J, et al. Effects of acute alcohol infusion on duration and dispersion of QT interval in male patients with coronary artery disease and in healthy controls. Clin Cardiol. 1999;22: 591-594.
56. Cardy MA, Donnerstein RL, Kelly LF, et al. Acute effects of ethanol ingestion on signal-averaged electrocardiograms. Am J Cardiol. 1996;77:1356-1357.
57. Sereny G. Effects of alcohol on the electrocardiogram. Circulation. 1971;44:558.
58. Ettinger PO, Wu CF, De La Cruz C, et al. Arrhythmias and the holiday heart:alcohol associated cardiac rhythm disorders. Am Heart J. 1978;95:555-562.
59. Greenspon AJ, Schaal SF. The "holiday heart":electrophysiological studies of alcohol effects in alcoholics. Ann Intern Med. 1983;98:135-139.
60. Engel TR, Luck JC. Effect of whiskey on atrial vulnerability and "holiday heart." J Am Coll Cardiol. 1983;1:816-818.
61. Denison H, Jern S, Jagenburg R, Wendestam C. Influence of increased adrenergic activity and magnesium depletion on cardiac rhythm in alcohol withdrawal. Br Heart J. 1994;72:554-560.
62. Khedun SM, Leary WP, Lockett CJ, Maharaj B. Changes in myocardial electrolytes and ventricular fibrillation threshold induced by alcohol feeding in lab rats. Jpn Heart J. 1991;32:373-379.
63. Malyutina S, Bobak M, Kurilovitch S, et al. Relation between heavy and binge drinking and all-cause and cardiovascular mortality in Novosibrisk, Russia: a prospective cohort. Lancet. 2002;360:1448-1454.
64. Yano K, Rhoads GG, Kagan A. Coffee, alcohol and risk of coronary artery disease among Japanese men living in Hawaii. N Engl J Med. 1977;297:405-409.
65. Stampfer MJ, Colditz GA, Willet WC, et al. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med. 1988;319:267-273.
66. Klatsky AL, Armstrong MA, Friedman GD. Relations of alcoholic beverage use to subsequent coronary artery disease hospitalization. Am J Cardiol. 1986;58:710-714.
67. Klatsky AL. Epidemiology of coronary heart disease:influence of alcohol. Alcohol Clin Exp Res. 1994;18:88-96.
68. Shaper AG. Alcohol and coronary heart disease. Eur Heart J. 1995; 16:1760-1764.
69. Neiman J, Rand ML, Jakowec DM, Packham MA. Platelet responses to platelet activating factor are inhibited in alcoholics undergoing alcohol withdrawal. Thromb Res. 1989;56:399-405.
70. Rimm EB, Giovanucci EL, Willett WC, Colditz GA. Prospective study of alcohol consumption and risk of coronary disease in men. Lancet. 1991;338:464-468.
71. Gaziano JM, Gaziano TA, Glynn RJ, et al. Light to moderate alcohol consumption and mortality in the Physicians Health Study enrollment cohort. J Am Coll Cardiol. 2000;35:96-105.
72. Mukamal KJ, Maclure M, Muller JE, et al. Prior alcohol consumption and mortality following acute myocardial infarction. JAMA. 2001;285: 1965-1970.
73. Muntwyler J, Hennekens CH, Buring JE, et al. Mortality and light to moderate alcohol consumption after myocardial infarction. Lancet. 1998;352:1882-1885.
74. Gronbaek M, Becker U, Johansen D, et al. Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. Ann Intern Med. 2000;133:411-419.
75. Albert CM, Manson JE, Cook NR, et al. Moderate alcohol consumption and the risk of sudden cardiac death among US male physicians. Circulation. 1999;100:944-950.
76. Ajani UA, Gaziano JM, Lotufo PA, et al. Alcohol consumption and risk of coronary heart disease in diabetic patients. Circulation. 2000;102: 500-505.
77. Solomon CG, Hu FB, Stampfer MJ, et al. Moderate alcohol consumption and risk of coronary heart disease among women with type 2 diabetes mellitus. Circulation. 2000;102:494-499.
78. Jackson R, Scragg R, Beaglehole R. Does recent alcohol consumption reduce the risk of acute myocardial infarction and coronary death in regular drinkers? Am J Epidemiol. 1992;136:819-824.
79. Mukamal KJ, Muller JE, Maclure M, et al. Lack of effect of recent alcohol consumption on the course of acute myocardial infarction. Am Heart J. 1999;138:926-933.
80. Klatsky AL. Should patients with heart disease drink alcohol? JAMA. 2001;285:2004-2006.
81. White IR. The level of alcohol consumption at which all-cause mortality is least. J Clin Epidemiol. 1999;52:967-975.
82. Romelsjö A, Leifman A. Association between alcohol consumption and mortality, myocardial infarction, and stroke in 25 year follow up of 49 618 young Swedish men. Br Med J. 1999;319:821-822.
83. Rimm EB, Williams P, Fosher K, et al. Moderate alcohol intake and lower risk of coronary heart disease:meta-analysis of effects on lipids and haemostatic factors. Br Med J. 1999;319:1523-1528.
84. Rubin R, Rand ML. Alcohol and platelet function. Alcohol Clin Exp Res. 1994;18:105-110.
85. Lacoste L, Hung J, Lam JYT. Acute and delayed antithrombotic effects of alcohol in humans. Am J Cardiol. 2001;87:82-85.
86. Rand ML, Groves HM, Packham MA, Mustard JF. Acute administration of ethanol to rabbits inhibits thrombus formation induced by indwelling aortic catheters. Lab Invest. 1990;63:742-745.
87. Rand ML, Neiman J, Jakowec DM, Packham MA. Effects of alcohol withdrawal on responses of platelets from alcoholic:a study using platelet-rich plasma from blood anticoagulated with D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone (FPRCH2C1). Thromb Hemost. 1990;63:178-182.
88. Elmer O, Goransson G, Zoucas E. Impairment of primary hemostasis and platelet function after alcohol ingestion in man. Haemostasis. 1984;14:223-228.
89. Mikhailidis DP, Barradas MA, Epemolu O, Dandona P. Ethanol ingestion inhibits human whole blood platelet impedance aggregation. Am J Clin Pathol. 1987;88:342-345.
90. Hutton RA, Fink R, Wilson DT, Marjot DH. Platelet hyperaggregability during alcohol withdrawal. Clin Lab Haematol. 1981;3:223-229.
91. Fink R, Hutton RA. Changes in the blood platelets of alcoholics during alcohol withdrawal. J Clin Pathol. 1983;36:337-340.
92. Desai K, Owen JS, Wilson DT, Hutton RA. Platelet aggregation and plasma lipoproteins in alcoholics during alcohol withdrawal. Thromb Haemost. 1986;55:173-177.
93. Rand ML, Groves HM, Kinlough-Rathbone RL. Effects of ethanol on rabbit platelets response to collagen in vitro and ex vivo on platelet adhesion. Thromb Res. 1987;48:379-388.
94. Mukamal KJ, Jadhav PP, D'Agostino RB, et al. Alcohol consumption and hemostatic factors. Analysis of the Framingham Offspring Cohort. Circulation. 2001;104:1367-1373.
95. Djousse L, Pankow JS, Arnett DK, et al. Alcohol consumption and plasminogen activator inhibitor type 1:the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J. 2000;139:704-709.
96. Nanchahal K, Ashton WD, Wood DA. Alcohol consumption, metabolic cardiovascular risk factors and hypertension in women. Int J Epidemiol. 2000;29:57-64.
97. van Tol A, Hendriks HFJ. Moderate alcohol consumption:effects on lipids and cardiovascular disease risk. Curr Opin Lipidol. 2001;12:19-23.
98. De Oliveira e Silva ER, Foster D, McGee Harper M, et al. Alcohol consumption raises HDL cholesterol levels by increasing the transport rate of apolipoproteins A-I and A-II. Circulation. 2000;102:2347-2352.
99. Valimaki M, Taskinen MR, Ylikahri R, Roine R. Comparison of the effects of two different doses of alcohol on serum lipoproteins, HDL subfractions and apolipoproteins AI and AII:a controlled study. Eur J Clin Invest. 1988;18:472-480.
100. Taskinen MR, Valimaki M, Nikkila EA, Kussi T. Sequence of alcohol induced initial changes in plasma lipoproteins (VLDL and HDL) and lipolytic enzymes in humans. Metab Clin Exp. 1985;34:112-119.
101. Nishiwaki M, Ishikawa T, Ito T, et al. Effects of alcohol on lipoprotein lipase, hepatic lipase, cholesteryl ester transfer protein, and lecithin: cholesterol acyltransferase in high-density lipoprotein cholesterol elevation. Atherosclerosis. 1994;111:99-109.
102. Hartung GH, Foreyt JP, Reeves RS, Krock LP. Effect of alcohol dose on plasma lipoprotein subfractions and lipolytic enzyme activity in active and inactive men. Metab Clin Exp. 1990;39:81-86.
103. Gaziano JM, Buring JE, Breslow JL, Goldhaber SZ. Moderate alcohol intake, increased levels of high density lipoprotein and its subfractions and decreased risk of myocardial infarction. N Engl J Med. 1994;330:1241-1242.
104. Valimaki M, Kahri J, Laitinen K, et al. High density lipoprotein subfractions apolipoprotein AI containing lipoproteins, lipoprotein (a), and cholesterol eset transfer protein activity in alcoholic women before and after withdrawal. Eur J Clin Invest. 1993;23:406-417.
105. Lamisse F, Schellenberg F, Bouyou E, Delarue J. Plasma lipids and alcohol consumption in alcoholic men. Alcohol Alcohol. 1994;29:25-30.
106. Hartung GH, Lawrence SJ, Reeves RS, Foreyt JP. Effect of alcohol and exercise on postprandial lipemia and triglyceride clearance in men. Atherosclerosis. 1993;100:33-40.
107. Guivernau M, Baraona E, Soong J, Lieber CS. Enhanced stimulatory effects of HDL and other agonists on vascular prostacyclin production in rats fed alcohol containing diets. Biochem Pharmacol. 1989;38:503-508.
108. Amarasuriya RN, Gupta AK, Civen M, et al. Ethanol stimulates apolipoprotein AI secretion by human hepatocytes:implication for mechanism for atherosclerosis protection. Metab Clin Exp. 1992;41: 827-832.
109. Malmendier CL, Delcroix C. Effect of alcohol intake on high and low density lipoprotein metabolism in healthy volunteers. Clin Chim Acta. 1985;152:281-288.
110. Savolainen MJ, Hannuksela AS, Kervinen SK, Kesaniemi YA. Increased HDL cholesterol concentration in alcoholics is related to low cholesteryl ester transfer protein activity. Eur J Clin Invest. 1990;20: 593-599.
111. Hannuksela M, Marcel YL, Kesaniemi A, Savoleinen MJ. Reduction in the concentration and activity of plasma cholesteryl ester transfer protein by alcohol. J Lipid Res. 1992;33:737-744.
112. Savolainen MJ, Hannuksela AS, Seppanen S, et al. Increased high density lipoprotein concentration in alcoholics is related to low cholesteryl ester transfer protein activity. Eur J Clin Invest. 1990;20:593-599.
113. Bhatnagar D, Durrington PN, Channon KM, Prais H. Increased transfer of cholesteryl esters from high density lipoproteins to low density and very low density lipoproteins in patients with angiographic evidence of coronary artery disease. Atherosclerosis. 1993;98:25-32.
114. Savolainen MJ, Kesaniemi YA. Effects of alcohol on lipoproteins in relation to coronary artery disease. Curr Opin Lipidol. 1995;6:243-250.
115. Castelli WP, Doyle JT, Gordon T, Hames CG. Alcohol and blood lipids, the cooperative lipoprotein phenotyping study. Lancet. 1977;2: 153-155.
116. Seitz HK, Kuhn B, von Hodenberg E, et al. Increased messenger RNA levels for low-density lipoprotein receptor and 3-hydroxy-3-methylglutaryl coenzyme A reductase in rat liver after long term ethanol ingestion. Hepatology. 1994;20:487-493.
117. Kesaniemi YA, Kervinen K, Miettinen TA. Acetaldehyde modification of low density lipoprotein accelerates its catabolism in man. Eur J Clin Invest. 1987;17:29-36.
118. Savolainen MJ, Baraona E, Lieber CS. Acetaldehyde binding increases the catabolism of rat serum low density lipoproteins. Life Sci. 1987; 40:841-846.
119. Pownall HJ, Ballantyne CM, Kimball KT, et al. Effect of moderate alcohol consumption on hypertriglyceridemia. A study in the fasting state. Arch Intern Med. 1999;159:981-987.
120. Marth E, Cazzolato G, BittoloBon G, et al. Serum concentration of Lp(a) and other lipoprotein parameters in heavy alcohol consumers. Ann Nutr Metab. 1982;26:56-62.
121. Criqui MH, Cowan LD, Tyroler HA, Bangdiwala S. Lipoproteins as mediators for the effects of alcohol consumption and cigarette smoking on cardiovascular mortality:results from the Lipid Research Clinics Follow up study. Am J Epidemiol. 1987;126:629-637.
122. Malarcher AM, Giles WH, Croft JB, et al. Alcohol intake, type of beverage, and the risk of cerebral infarction in young women. Stroke. 2001;32:77-83.
123. Sacco RL, Elkind M, Boden-Albala B, et al. The protective effect of moderate alcohol consumption on ischemic stroke. JAMA. 1999;281: 53-60.
124. Berger K, Ajani UA, Kase CS, et al. Light-to-moderate alcohol consumption and the risk of stroke among U. S. male physicians. N Engl J Med. 1999;341:1557-1564.
125. Leppälä JM, Paunio M, Virtamo J, et al. Alcohol consumption and stroke incidence in male smokers. Circulation. 1999;100:1209-1214.
126. Djoussé L, Levy D, Murabito JM, et al. Alcohol consumption and risk of intermittent claudication in the Framingham Heart Study. Circulation. 2000;102:3092-3097.
127. Abramson JL, Williams SA, Krumholz HM, Vaccarino V. Moderate alcohol consumption and risk of heart failure among older persons. JAMA. 2001;285:1971-1977.
128. Cooper HA, Exner DV, Domanski MJ. Light to moderate alcohol consumption and prognosis in patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000;35:1753-1759.
129. Wollin SD, Jones PJH. Alcohol, red wine and cardiovascular disease. Am Soc Nutri Sci. 2001;131:1401-1404.
130. Sato M, Ray PS, Maulik G, et al. Myocardial protection with red wine extract. J Cardiovasc Pharmacol. 2000;35:263-268.
131. Agewall S, Wright S, Doughty RN, et al. Does a glass of red wine improve endothelial function? Eur Heart J. 2000;21:74-78.
132. Gaziana JM, Hennekens CH, Godfried SL, et al. Type of alcoholic beverage and risk of myocardial infarction. Am J Cardiol. 1999;83:52-57.
133. Iijima K, Yoshizumi M, Hashimoto M, et al. Red wine polyphenols inhibit proliferation of vascular smooth muscle cells and downregulate expression of cyclin A gene. Circulation. 2000;101:805-811.
134. Bentzon JF, Skovenborg E, Hansen C, et al. Red wine does not reduce mature atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2001;103:1681-1687.
135. Benaud SC, Gueguen R, Siest G, Salamon R. Wine, beer, and mortality in middle-aged men from eastern France. Arch Intern Med. 1999;159: 1865-1870.
136. Feng A-N, Chen Y-L, Chen Y-T, et al. Red wine inhibits monocyte chemotactic protein-1 expression and modestly reduced neointimal hyperplasia after balloon injury in cholesterol-fed rabbits. Circulation. 1999;100:2254-2259.
137. Blanco-Colio LM, Valderrama M, Alvarez-Sala LA, et al. Red wine intake prevents nuclear factor κB activation in peripheral blood mononuclear cells of healthy volunteers during postprandial lipemia. Circulation. 2000;102:1020-1026.
138. Goldberg IJ, Mosca L, Piano MR, Fisher EA. Wine and your heart. A Science Advisory for Healthcare Professionals from the Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the American Heart Association. Circulation. 2001;103:472-475.
139. Kosten TR, Hollister LE. Drugs of abuse. In: Katzung BG, ed. Basic & Clinical Pharmacology, 8th ed. Norwalk: Appleton & Lange; 2000: 532-548.
140. Hong R, Matsuyama E, Nur K. Cardiomyopathy associated with the smoking of crystal methamphetamine. JAMA. 1991;265:1152-1154.
141. Dowling GP, McDonough ET, Bost RO. "Eve" and "ecstasy." A report of five deaths associated with the use of MDEA and MDNA. JAMA. 1987;257:1615-1617.
142. Lester SJ, Baggott M, Welm S, et al. Cardiovascular effects of 3, 4-methylenedioxy-methamphetamine. A double-blind, placebo-controlled trial. Ann Intern Med. 2000;133:969-973.
143. Committee on Alcoholism and Addiction and Council on Mental Health. Dependence on amphetamines and other stimulant drugs. JAMA. 1966;197:1023.
144. Badon LA, Hicks A, Lord K, et al. Changes in cardiovascular responsiveness and cardio-toxicity elicited during binge administration of ecstasy. J Pharmacol Exp Ther. 2002;302:898-907.
145. Schaiberger PH, Kennedy TC, Miller FC, et al. Pulmonary hypertension associated with long term inhalation of "crank" methamphetamine. Chest. 1993;104:614-616.
146. Davis GG, Swalwell CI. Acute aortic dissections and ruptured berry aneurysms associated with methamphetamine abuse. J Forensic Sci. 1994;39:1481-1485.
147. Duflou J, Mark A. Aortic dissection after ingestion of "ecstasy" (MDMA). Am J Forensic Med Pathol. 2000;21:261-263.
148. Suarez RV, Riemersma R. "Ecstasy" and sudden cardiac death. Am J Forensic Med Pathol. 1988;9:339-341.
149. Smith HJ, Roche AH, Jausch MF, Herdson PB. Cardiomyopathy associated with amphetamine administration. Am Heart J. 1976;91:792-797.
150. Jacobs LJ. Reversible dilated cardiomyopathy induced by methamphetamine. Clin Cardiol. 1989;12:725-727.
151. O'Neill ME, Arnolda LF, Coles DM, Nikolic G. Acute amphetamine cardiomyopathy in a drug addict. Clin Cardiol. 1983;6:189-191.
152. Call TD, Hartneck J, Dickinson WA, et al. Acute cardiomyopathy secondary to intravenous amphetamine. Ann Intern Med. 1982;97:559-560.
153. Eagan TS, Watson RR. Methamphetamine in heart disease. Cardiovasc Rev Rep. 2002;23:320-324.
154. Kahn DS, Roma G, Chappel CI. Isoproterenol induced cardiac necrosis. Ann NY Acad Sci. 1969;156:286.
155. Pearce RM. Experimental myocarditis: a study of the histological changes following intravenous injections of adrenalin. J Exp Med. 1906;8:400.
156. Factor SM, Sonnenblick EH. The pathogenesis of clinical and experimental congestive cardiomyopathies:recent concepts. Prog Cardiovasc Dis. 1985;27:395-420.
157. Imperato-McGinley J, Gautier T, Ehlers K, et al. Reversibility of catecholamine induced dilated cardiomyopathy in a child with pheochromocytoma. N Engl J Med. 1987;316:793-797.
158. Ragland AS, Ismail Y, Arsura EL. Myocardial infarction after amphetamine use. Am Heart J. 1993;12:247-249.
159. Packe GE, Garton MJ, Jennings K. Acute myocardial infarction caused by intravenous amphetamine abuse. Br Heart J. 1990;64:23-24.
160. Qasim A, Townsend J, Davies MK. Ecstasy induced acute myocardial infarction. Heart. 2001;85:e10.
161. Waksman J, Taylor RN Jr, Bodor GS, et al. Acute myocardial infarction associated with amphetamine use. Mayo Clin Proc. 2001;76:323-326.
162. Bashour TT. Acute myocardial infarction resulting from amphetamine abuse:spasm-thrombus interplay? Am J Heart J. 1994;128:1237-1239.
163. Trugman JM. Cerebral arteritis and oral methylphenedate. Lancet. 1988;1:584-585.
164. Brashear RE, Cornog JL, Forney RB. Cardiovascular effects of heroin in the dog. Anesth Analg. 1973;52:323-327.
165. Pur-Shahriari AA, Mills RA, Hoppin FG, et al. Comparison of chronic and acute effect of morphine sulfate on cardiovascular function. Am J Cardiol. 1967;20:654-659.
166. Paterna S, Di Pasquale P, Montaina G, et al. Effect of heroin and morphine on cardiac performance in isolated and perfused rabbit heart:evaluation of cardiac hemodynamics, myocardial enzyme activity and ultrastructural features. Cardiologia. 1991;36:811-815.
167. Lipski J, Stimmel B., Donoso E. The effect of heroin and multiple drug abuse on the electrocardiogram. Am Heart J. 1973;86:663-668.
168. Krantz MJ, Lewkowiez L, Hays H, et al. Torsade de pointes associated with very-high-dose methadone. Ann Intern Med. 2002;137:501-504.
169. Siegel H. Human pulmonary pathology associated with narcotic and other addictive drugs. Hum Pathol. 1972;3:55-66.
170. Sporer KA, Dorn E. Heroin overdose related noncardiogenic pulmonary edema. A case series. Chest. 2001;120:1628-1632.
171. Peon J, Ruiz-Gonzalez M. Electrophysiological effects of morphine, naloxone, and comorphone on cardiac Purkinje fibers. Proc West Pharmacol Soc. 1991;34:255-259.
172. Substance Abuse and Mental Health Services Administration. National Household Survey on Drug Abuse. Rockville, MD: SAMHSA Office of Applied Sciences; 1998. DHHS No. (SMA)99-3328 1999.
173. Jones RT: Cardiovascular system effects of marijuana. J Clin Pharmacol. 2002;42:58S-63S.
174. Williamson EM, Evans FJ. Cannabinoids in clinical practice. Drugs. 2000;60:1303-1314.
175. Miller RH, Dhingra RC, Kanakis C, et al. The electrophysiological effects of delta-9-tetrahydrocannabinol(cannabis) on cardiac conduction in man. Am Heart J. 1977;94:740-747.
176. Johnson S, Domino EF. Some cardiovascular effects of marihuana smoking in normal volunteers. Clin Pharmacol Ther. 1971;12:762-768.
177. Kiplinger G, Manno JE, Rodda BE, Forney RB. Dose response analysis of the effects of tetrahydrocannabinol in man. Clin Pharmacol Ther. 1971;12:650-657.
178. Roth WT, Tinkleinberg JR, Kopell BS, Hollister LE. Continuous electrocardiographic monitoring during marihuana intoxication. Clin Pharmacol Ther. 1973;14:533-540.
179. Voth EA, Schwartz R-H. Medicinal applications of delta-9-tetrahydro-cannabinol and marijuana. Ann Intern Med. 1997;126:791-798.
180. Mathew RJ, Wilson WH, Humphreys D, et al. Middle cerebral artery velocity during upright posture after marijuana smoking. Acta Psychiatr Scand. 1992;86:173-78.
181. Akins D, Awdeh MR. Marijuana and second degree AV block. South Med J. 1981;74:371-373.
182. Charles R, Holt S, Kirkham N. Myocardial infarction and marijuana. Clin Toxic. 1979;14:433-438.
183. Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation. 2001;103:2805-2809.
184. Gottschalk LA, Aronow WS, Prakesh R. Effect of marijuana smoking on psychological state and on psychophysiological cardiovascular functioning in anginal patients. Bio Psychiatry. 1977;12:255-266.
185. Sidney S. Cardiovascular consequences of marijuana use. J Clin Pharmacol. 2002;42:64S-70S.
186. Benowitz NL, Jones RT. Cardiovascular effects of prolonged delta-9-tetrahydrocannabinol ingestion. Clin Pharm Ther. 1975;18:287-297.
187. Avakian EV, Horvath SM, Michael ED, Jacobs S. Effects of marihuana on cardiorespiratory responses to submaximal exercise. Clin Pharm Ther. 1979;26:777-781.
188. Clark SC. Marijuana and the cardiovascular system. Pharmacol Biochem Behav. 1975;3:299-306.
189. Solowij N, Stephens RS, Roffman RA, et al, for the Marijuana Treatment Project Research Group. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA. 2002;287:1123-1131.
190. Chou T. Wake up and smell the coffee. Caffeine, coffee and medical consequences. West J Med. 1992;157:544-553.
191. Schneider JR: Effects of caffeine ingestion on heart rate, blood pressure, myocardial oxygen consumption, and cardiac rhythm in acute myocardial infarction patients. Heart Lung. 1987;16:167-174.
192. Schneider JR. Should patients with myocardial infarction receive caffeinated coffee? Focus Crit Care. 1988;15:52-61.
193. Bunker ML, McWilliams M. Caffeine content of common beverages. J Am Diet. 1979;74:28-32.
194. Curatolo PW, Robertson D. The health consequences of caffeine. Ann Intern Med. 1983;98:641-653.
195. Graham DM. Caffeine. its identity, dietary sources, intake and biological effects. Citation. 1978;36:97-102.
196. Fredholm BB, Persson CGA. Xanthine derivatives as adenosine receptor antagonists. Eur J Pharmacol. 1982;81:673-676.
197. Serafin W. Drugs used in the treatment of asthma. Goodman & Gilman's The Pharmacological Basis of Therapeutics, In: Hardman JG Limbird LE9th ed. 1996673 McGraw Hill New York
198. Myers MG. Effects of caffeine on blood pressure. Arch Intern Med. 1988;148:1189-1193.
199. Bottcher M, Czemin J, Sun K, Phelps ME, Schelbert H. Effect of caffeine on myocardial blood flow at rest and during pharmacological vasodilation. J Nucl Med. 1995;36:2016-2021.
200. vanDam RM, Feskens EJM. Coffee consumption and risk of type 2 diabetes mellitus (letter). Lancet. 2002;360:1477-1478.
201. Rakic V, Burke V, Beilin LJ. Effects of coffee on ambulatory blood pressure in older men and women. Hypertension. 1999;33:869-873.
202. Hartley TR, Sung BH, Pincomb GA, et al. Hypertension risk status and effect of caffeine on blood pressure. Hypertension. 2000;36:137-141.
203. Sollman T, Pilcher JD. The actions of caffeine on the mammalian circulation. J Pharmacol Exp Ther. 1911;3:19.
204. Starr I, Gamble CJ, Margolies A. A clinical study of the action of 10 commonly used drugs on cardiac output, work and size on respiration, on metabolic rate and on the electrocardiogram. J Clin Invest. 1937; 16:799-823.
205. Gould L, Venkataraman K, Goswami M, Gomprecht RF. The cardiac effects of coffee. Angiology. 1973;24:455-463.
206. Higgins HL, Means JH. The effect of certain drugs on the respiration and gaseous metabolism in normal human subjects. J Pharmacol Exp Ther. 1915;7:1-30.
207. a. Sondermeijer HP, vanMarle AGJ, Kamen P, et al. Acute effects of caffine on heart rate variability. Am J Cardiol. 2002;90:906-907.
208. Bellet S, Roman L, Decastro O, et al. Effect of coffee ingestion on catecholamine release. Metabolism. 1969;18:288-291.
209. Jung RT, Shetty PS, James WPT, et al. Caffeine:its effects on catecholamines and metabolism in lean and obese humans. Clin Sci. 1981;60:527-535.
210. Pincomb GA, Lovallo WR, Passey RB. Effects of caffeine on vascular resistance, cardiac output and myocardial contractility in young men. Am J Cardiol 1985;56:119-122.
211. Mahmud Z, Feely J. Acute effect of caffeine on arterial stiffness and aortic pressure waveform. Hypertension. 2001;38:227-231.
212. Klatsky AL, Friedman GD, Siegelaub AB. Coffee drinking prior to acute myocardial infarction. Results from the Kaiser Permanente Epidemiologic Study of Myocardial Infarction. JAMA 1973;226:540-543.
213. Walker WJ, Gregoratos SG. Myocardial infarction in young men. Am J Cardiol. 1967;19:339-343.
214. Brown A. Coronary thrombosis: an environmental study. Br Med J. 1962;2:567.
215. Paul O, Leper MH, Phelan W, et al. A longitudinal study of coronary heart disease. Circulation. 1963;28:20-31.
216. Coffee drinking and acute myocardial infarction. Report from Boston Collaborative Drug Surveillance Program. Lancet. 1972;2:1278-1281.
217. Jick H, Miettinen OS, Neff R, et al. Coffee and myocardial infarction. N Engl J Med. 1973;289:63-67.
218. Mann JJ, Thorogood M. Coffee drinking and myocardial infarction, Lancet. 1975;2:1215.
219. Hennenkens CH, Drolette ME, Jesse MJ, et al. Coffee drinking and death due to coronary heart disease. N Engl J Med. 1976;294:633-636.
220. Wilhelmsen L, Tibblin G, Elmfeldt D, Werkol WH. Coffee consumption and coronary heart disease in middle-aged Swedish men. Acta Med Scand 1977;201:547-552.
221. Heyden S, Tyroler HA, Heiss G, et al. Coffee consumption and mortality. Arch Intern Med. 1978;138:1472-1475.
222. Murray SS, Bjelke E, Gibson RW, Schuman LM. Coffee consumption and mortality from ischemic heart disease and other causes:results from the Lutheran Brotherhood Study, 1966-1978. Am J Epidemiol. 1981;113:661-667.
223. LaCroix AZ, Mead LA, Kung-Yee L, et al. Coffee consumption and the incidence of coronary heart disease. N Engl J Med. 1986;315:977-982
224. Rosmarin PC, Applegate WB, Somes GW. Coffee consumption and serum lipids:a randomized crossover clinical trial. Am J Med. 1990;88:349-356.
225. Grobbee DE, Rimm EB, Giovannucci E, et al. Coffee, caffeine and cardiovascular disease in men. N Engl J Med. 1990;323:1026-1032.
226. Jacobsen BK, Bjelke E, Kvale G, Hench I. Coffee drinking, mortality and cancer incidence:results from a Norwegian prospective study. J Natl Cancer Inst. 1986;76:823-826.
227. LeGrady D, Dyer AR, Schekelle RB, et al. Coffee consumption and mortality in Chicago. Western Electric Company Study. Am J Epidemiol. 1987;126:803-812.
228. Reed DM, MacLean CJ, Hayashi T. Predictors of atherosclerosis in the Honolulu Heart Program. I. Biologic, dietary and life style characteristics. Am J Epidemiol. 1987;126:214-225.
229. Wilson PW, Garrison RJ, Kannel WB, et al. Is coffee consumption a contributor to cardiovascular disease? Insights from the Framingham study. Arch Intern Med. 1989:149:1169-1172.
230. Willett WC, Stampfer MJ, Manson JE, et al. Coffee consumption and coronary artery disease in women. A 10 year follow up. JAMA. 1996;275:458-462.
231. Klatsky AL, Friedman GD, Armstrong MA. Coffee use prior to myocardial infarction restudied:heavier intake may increase the risk. Am J Epidemiol. 1990;132:479-488.
232. Rosengren A, Wilhelmsen L. Coffee, coronary heart disease and mortality in middle-aged Swedish men: Findings from the Primary Prevention Study. J Intern Med. 1991;230:67-71.
233. Lindsted KD, Kuzma JW, Anderson JL. Coffee consumption and cause-specific mortality:association with age at death and compression of mortality. J Clin Epidemiol. 1992;45:733-742.
234. Sesso HD, Gaziano JM, Burning JE, Hennekens CH. Coffee and tea intake and the risk of myocardial infarction. Am J Epidemiol. 1999; 149:162-167.
235. Duffy SJ, Keaney JF, Holbrook M, et al. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation. 2001;104:151-156.
236. Mukamal KJ, Maclure M, Muller JE. Tea consumption and mortality after acute myocardial infarction. Circulation. 2002;105:2476-2481.
237. Prineas RJ, Jacobs Jr. DR, Crow RS, Blackburn H. Coffee, tea and VPB. J Chronic Dis. 1980;33:67-72.
238. Donnerstein RL, Zhu D, Samson R, et al. Acute effects of caffeine ingestion on signal-averaged electrocardiograms. Am Heart J. 1998; 136:643-646.
239. Myers MG, Harris L, Leenen FHH, Grant DM. Caffeine as a possible cause of ventricular arrhythmias during the healing phase of acute myocardial infarction. Am J Cardiol. 1987;59:1024-1028.
240. Grubben MJ, Boers GH, Blom HJ, et al. Unfiltered coffee increases plasma homocysteine concentrations in healthy volunteers:a randomized trial. Am J Clin Nutr. 2000;71:480-484.
241. de Roos B, Katan MB. Possible mechanisms underlying the cholesterol-raising effect of the coffee diterpene cafestol. Curr Opin Lipidol. 1999;10:41-45.
242. Heishman SJ, Henningfield JE. Stimulus functions of caffeine in humans:relation to dependence potential. Neurosci Biobehav Rev. 1992;16:273-287.
243. Abbott PJ. Caffeine:a toxicological overview. Therapeutics. 1986;145: 518-521.
244. Robertson D, Wade D, Workman R, et al. Tolerance to the humpral and hemodynamic effects of caffeine in man. J Clin Invest. 1981;67:1111-1117.
245. Green RM, Stiles GL. Chronic caffeine consumption sensitized the Al adenosine receptor-adenylate cyclase system in rat cerebral cortex. J Clin Invest. 1986;77:222-227.
246. Griffiths RR, Woodson PP. Reinforcing properties of caffeine studies in humans and laboratory animals. Pharmacol Biochem Behav. 1988; 29:419-427.
247. Leier C. Positive inotropic therapy. Curr Probl Cardiol. 1996;21:523.